ITCI - intracellulartherapies.com Debt to Book Capitalization Ratio

Brandmark of Intra-Cellular Therapies Inc. (ITCI)

Intra-Cellular Therapies (ITCI) is shaping the modern landscape of psychiatric treatment by integrating Caplyta into clinical protocols. The financing structure, specifically the debt-to-book capitalization ratio, clearly demonstrates financial stability, while the 0.01 value reflects the metric's balance. The company leverages cutting-edge R&D in neurobiology, and the growing sales of its flagship product effectively optimize costs, increasing the business's bottom-line margins.

Intra-Cellular Therapies, Inc. (ITCI) - Debts to Book Value from 07/04/2022 to 04/13/2025
Mass-produced product of Intra-Cellular Therapies Inc.

This ratio determines the financial stability of an asset through the relationship between total debt and the book value of equity. The metric measures the proportion of borrowed funds within the equity structure, identifying default risks or the underutilization of leverage. By analyzing the debt-to-capitalization coverage ratio, an investor assesses the balance between safety and expansion. For Intra-Cellular Therapies (ITCI), a low debt load is critical when scaling Caplyta sales. This allows the company to increase margins without overburdening the budget with debt service while awaiting new catalysts.

Competitors of Intra-Cellular Therapies

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|VKTX: Debts to Book Capitalization|Debts to Net Assets SUPN|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc. CPRX|Debt to Book Value Ratio Denali DNLI|Debt to Book Value Harmony Pharma (HRMY)|Biohaven Corp - Debt to Book Capital|Debt to Book Capitalization Ratio Amylyx Pharmaceuticals (AMLX)|TRVI - Debt to Net Assets Ratio|PRAX: Debts to Book Capitalization|Debts to Book Capitalization Anavex|CeriBell Corp - Debt to Book Value|Debt to Net Assets prothena.com|Debts to Book Capitalization ALEC (Alector, Inc.)|Debt to Book Value annexonbio.com (ANNX)|OMER: Debts to Book Capitalization|Neurogene Inc - Debts to Book Value|ACIU - Debt to Book Capitalization Ratio|VYGR: Debt to Book Capitalization Ratio|Neumora Therapeutics (NMRA) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio scilexholding.com|TVGN (Tevogen Bio) - Debt to Book Value|Debts to Book Capitalization ACOG|Debt to Book Capitalization Ratio Cognition Therapeutics (CGTX)|Debt to Book Capitalization Ratio Inhibikase Pharma (IKT)|Debts to Book Capitalization SAVA (Cassava Sciences, Inc.)|Assertio Holdings - Debts to Book Capitalization|Debt to Book Capitalization Ratio Coya (COYA)|Vistagen Therapeutics (VTGN) - Debt to Net Assets Ratio|Debt to Book Value ovidrx.com OVID|Debt to Net Assets Ratio Acumen Pharmaceuticals, Inc|CervoMed Inc. (CRVO) - Debt to Book Value|Debt to Book Capital Alterity Therapeutics Ltd|Clene Inc. (CLNN) - Debts to Book Capitalization|Debt to Net Assets Ratio pepgen.com (PEPG)|JUNS: Debts to Book Capitalization|Relmada Corp - Debts to Book Value|Debt to Book Capitalization Ratio Annovis Bio, Inc. (ANVS)|GRCE - Debt to Net Assets Ratio|AIFF: Debts to Book Capitalization|KLTO (Klotho Neurosciences) - Debts to Book Capitalization|Debt to Book Capitalization Ratio NeuroSense Therapeutics Ltd NRSN|Debts to Book Capitalization Ratio Reviva Pharmaceuticals, Inc.|MTVA (MetaVia Inc) - Debts to Book Capitalization|Debts to Net Assets neuraxis.com (NRXS)|HSDT: Debts to Book Capitalization|Passage Bio Inc. - Debts to Book Value|Debt to Book Capitalization Ratio NEUP (Neuphoria)|NERV - Debts to Net Assets|Athira Pharma, Inc. - Debts to Book Capitalization|Debts to Net Assets addextherapeutics.com|Alzamend Neuro Inc. (ALZN) - Debt to Book Value|Debt to Book Capital Cyclerion|Debts to Book Capitalization PTIX (Protagenic Therapeutics)|Debt to Book Value pasitheaclinics.com (KTTA)|Debts to Book Capitalization CRGT|avenuetx.com - Debts to Net Assets|BrainStorm Cell Therapeutics (BCLI) - Debt to Book Capitalization Ratio|CARA - Debt to Book Value Ratio|Debts to Book Capitalization CHRO|Debts to Book Value Eliem Therapeutics Inc.|LBPH (Longboard Pharmaceuticals) - Debt to Book Value|Debts to Book Capitalization MRNS|NKGen Biotech (NKGN) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NRBO (NeuroBo Pharmaceuticals Inc)|SAGE: Debt to Book Capitalization Ratio|Debts to Book Value Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|VIGL: Debts to Net Assets|Debt to Book Capitalization Ratio Anew Medical|Debt to Book Value Ratio Cerevel Therapeutics Inc